A model-based assessment of the cost-utility of strategies to identify Lynch syndrome in early-onset colorectal cancer patients by Snowsill, T. et al.
Snowsill et al. BMC Cancer  (2015) 15:313 
DOI 10.1186/s12885-015-1254-5RESEARCH ARTICLE Open AccessA model-based assessment of the cost–utility of
strategies to identify Lynch syndrome in
early-onset colorectal cancer patients
Tristan Snowsill1*, Nicola Huxley1, Martin Hoyle1, Tracey Jones-Hughes1, Helen Coelho1, Chris Cooper1,
Ian Frayling2 and Chris Hyde1Abstract
Background: Lynch syndrome is an autosomal dominant cancer predisposition syndrome caused by mutations in
the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2. Individuals with Lynch syndrome have an increased
risk of colorectal cancer, endometrial cancer, ovarian and other cancers. Lynch syndrome remains underdiagnosed in
the UK. Reflex testing for Lynch syndrome in early-onset colorectal cancer patients is proposed as a method to identify
more families affected by Lynch syndrome and offer surveillance to reduce cancer risks, although cost-effectiveness is
viewed as a barrier to implementation. The objective of this project was to estimate the cost–utility of strategies to
identify Lynch syndrome in individuals with early-onset colorectal cancer in the NHS.
Methods: A decision analytic model was developed which simulated diagnostic and long-term outcomes over a
lifetime horizon for colorectal cancer patients with and without Lynch syndrome and for relatives of those patients.
Nine diagnostic strategies were modelled which included microsatellite instability (MSI) testing, immunohistochemistry
(IHC), BRAF mutation testing (methylation testing in a scenario analysis), diagnostic mutation testing and Amsterdam II
criteria. Biennial colonoscopic surveillance was included for individuals diagnosed with Lynch syndrome and accepting
surveillance. Prophylactic hysterectomy with bilateral salpingo-oophorectomy (H-BSO) was similarly included for women
diagnosed with Lynch syndrome. Costs from NHS and Personal Social Services perspective and quality-adjusted life
years (QALYs) were estimated and discounted at 3.5% per annum.
Results: All strategies included for the identification of Lynch syndrome were cost-effective versus no testing. The
strategy with the greatest net health benefit was MSI followed by BRAF followed by diagnostic genetic testing, costing
£5,491 per QALY gained over no testing. The effect of prophylactic H-BSO on health-related quality of life (HRQoL) is
uncertain and could outweigh the health benefits of testing, resulting in overall QALY loss.
Conclusions: Reflex testing for Lynch syndrome in early-onset colorectal cancer patients is predicted to be a
cost-effective use of limited financial resources in England and Wales. Research is recommended into the
cost-effectiveness of reflex testing for Lynch syndrome in other associated cancers and into the impact of
prophylactic H-BSO on HRQoL.
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Lynch syndrome (LS; previously known as hereditary non-
polyposis colorectal cancer, HNPCC) is an autosomal-
dominant cancer predisposition syndrome caused by
mutations in the DNA mismatch repair (MMR) genes
MLH1, MSH2, MSH6 and PMS2 [1]. LS predisposes to
colorectal cancer (CRC) as well as extracolonic cancers
including endometrial cancer and ovarian cancer
(see Table 1).
Cancer prevention strategies can be employed for indi-
viduals with LS which benefit both individuals already
affected by cancer and also those unaffected, yet LS re-
mains underdiagnosed in the UK, in which there is no
universal systematic testing for LS.
The National Institute for Health Research Health Tech-
nology Assessment Programme was asked to commission
research into the cost-effectiveness of systematic testing for
LS in individuals with newly diagnosed early-onset CRC
and here we report the results of that research.
Diagnosis
The diagnosis of LS rests on the results of microscopic
and molecular tests. Microsatellite instability (MSI) in
tumour tissue indicates a loss of MMR proficiency, while
immunohistochemistry (IHC) of MMR proteins can in-
dicate loss of their expression in a tumour; both indicate
LS as a possible cause of the tumour. Sporadic tumours
with MSI or lack of MMR protein expression also occur,
so adjunctive tests such as for the BRAF V600E muta-
tion and hypermethylation of the MLH1 promotor can
reduce false-positive results.
Although LS can be strongly suspected on the basis of
personal and family history (such as the Amsterdam II
criteria and revised Bethesda criteria) [1] allied with the
results of tumour testing, ideally the finding of a patho-
genic mutation in one of the DNA MMR genes is neces-
sary for a firm diagnosis. The current standard for
diagnostic testing for MMR mutations is DNA sequencing
(to detect point mutations and small insertions/deletions)
and multiplex ligation-dependent probe amplification
(MLPA; to detect large structural DNA abnormalities).
The finding of a pathogenic mutation is a prerequisite for
predictive testing of relatives.Table 1 Cumulative risk to age 70 of selected Lynch
syndrome associated cancers
Cancer Risk to age 70 (95% CI)
Colorectal cancer (men) 38% (25%–59%)
Colorectal cancer (women) 31% (19%–50%)
Endometrial cancer (women) 33% (16%–57%)
Ovarian cancer (women) 9% (4%–31%)
Source: Bonadona et al. [45].
Notes: Estimates do not include PMS2 mutation carriers.The interpretation of a mutation as pathogenic is com-
plex and not always possible, although a significant recent
advance has been made with a standardised classification
scheme [2].
To avoid psychological harm, the genetic testing of in-
dividuals for constitutional mutations responsible for a
cancer predisposition syndrome should only take place
after informed consent and genetic counselling [3].
There are thousands of unique MMR DNA variants,
although a proportion of these (around 11%) are not
pathogenic or likely not pathogenic and a proportion
(around 32%) have unknown significance (i.e., could be
pathogenic but not confirmed) [2]. Screening for MMR
mutations in unaffected individuals (i.e., in the general
population) is generally thought to be prohibitively ex-
pensive and ill-advised due to the prevalence of vari-
ants of unknown significance and the lack of evidence
regarding the psychological impact of such results.
Screening is therefore reserved for individuals thought
likely to have LS.Management
If LS is identified in an individual, surveillance can be of-
fered to reduce the risk of CRC. UK guidelines state that
“Total colonic surveillance (at least biennial) should com-
mence at age 25 years. […] Surveillance should continue
to age 70–75 years or until comorbidity makes it clinically
inappropriate”. [4] High quality data from randomised tri-
als is not available regarding the effectiveness of colono-
scopic surveillance, but the best available published
evidence suggests a 62% reduction in the risk of CRC for
individuals with LS undergoing 3-yearly colonoscopy in
Finland [5,6]. Despite the evidence showing that colorectal
surveillance is effective in LS, recent work shows that
there is poor compliance in the UK with international
guidelines, with inadequate assessment and wide variabil-
ity in the management of LS [7].
Evidence is lacking to support prophylactic surgery
to prevent CRC or the practice of aggressive surgery
(removing significantly more of the colorectum than
necessary for treatment alone) for CRC, although the
latter is recommended in the BSG/ACPGBI guidelines
[4]. Likewise evidence is lacking to support surveil-
lance for gynaecological cancers yet this too is recom-
mended in guidelines [6]. There is evidence to support
prophylactic surgery (H-BSO) to prevent gynaeco-
logical cancers [8], although impact on health-related
quality of life (HRQoL) has not been assessed; guide-
lines have not recommended prophylactic surgery but
have suggested it be presented as an option [6]. Rec-
ommendations are also made regarding surveillance
for other cancers associated with LS, but without sup-
porting evidence [6].
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To estimate the cost–utility of strategies to identify LS
in early-onset CRC (aged under 50 years) in the NHS in
England and Wales.
Methods
We developed a decision analytic model in consultation
with clinical experts (co-author Dr Ian Frayling; ac-
knowledged contributors Mr Ian Daniels, Dr Carole
Brewer and Mr John Renninson, all of Royal Devon &
Exeter NHS Trust) and parameterised using the best
available data relevant to the NHS.
Population
Individuals in England and Wales newly diagnosed with
CRC aged under 50 years (denoted probands) and their
relatives, who would be offered predictive genetic testing
if a LS mutation was found in a proband.
Interventions
Nine diagnostic strategies for LS were chosen on the
basis of the tests available, strategies in previous cost-
effectiveness models and expert advice. Due to the lack
of clearly defined current practice, two strategies were
included in which genetic testing is not offered; in the
first of these no attempt was made to identify LS in the
probands, and in the second the Amsterdam II criteria
were used. The final set of strategies was:
1. Strategies without genetic testing
1(1). No testing at all (all diagnosed LS negative)
2(2). Amsterdam II criteria for diagnosis
2. IHC four-panel test for MLH1, MSH2, MSH6 and
PMS2, followed by mutation testing if IHC result
abnormal
3. IHC four-panel test, followed by BRAF V600E
mutation testing if MLH1 abnormal and mutation
testing if MMR protein other than MLH1 abnormal
or BRAF V600E mutation not found
4. MSI testing, followed by mutation testing if MSI
found
5. MSI testing, followed by BRAF V600E mutation
testing if MSI found, followed by mutation testing if
BRAF V600E mutation not found
6. As Strategy 5 but IHC performed in parallel with
mutation testing to aid interpretation (i.e., not used
diagnostically)
7. IHC four-panel test followed by mutation testing if
IHC result abnormal. If IHC result normal, follow
Strategy 5
8. Direct mutation testing.
Mutation testing for LS includes both sequencing and
MLPA. Probands would be classified as LS positive if amutation was found or LS assumed if no mutation was
found but LS was suspected on the basis of family his-
tory. In addition probands could decline genetic coun-
selling or diagnostic genetic testing and in this case
would be classified as LS assumed or LS negative on the
basis of family history.
When LS mutations were found in probands, testing
was offered to their first-degree relatives (FDRs). Where
the family mutation was also found in those FDRs, cas-
cade testing was used to reach more distant relatives.
When probands were assumed to have LS, only their
FDRs were assumed to have Lynch syndrome.
Individuals classified as LS positive or LS assumed
would be offered biennial colonoscopic surveillance com-
mencing at age 25 and ending at age 75.
Outcomes
The primary outcomes were the expected total costs and
quality-adjusted life years (QALYs) for each diagnostic
strategy, the incremental cost-effectiveness ratios (ICERs)
of the strategies and the incremental net health benefit
(INHB) of the strategies at a willingness-to-pay of £20,000
per QALY.
Secondary outcomes were the diagnostic test accuracies
of the strategies, the expected number of colonoscopies
and cancers in each strategy, and the life expectancy in
each strategy.
Study design
We developed a decision analytic model with two
components.
The first component (the diagnostic submodel) con-
sisted of a decision tree and was used to estimate the
number of probands and relatives who would receive
each possible diagnosis and to estimate how many indi-
viduals diagnosed with Lynch syndrome would accept
colonoscopic surveillance for each of the strategies listed
in Interventions (above). It also calculated the cost of
diagnosis in each strategy.
The second component (the management submodel)
consisted of an individual patient simulation and was used
to estimate the lifetime costs that would be incurred
through colonoscopies, CRC treatment, hysterectomies
(note these also include bilateral salpingo-oophorectomy)
and endometrial cancer treatment and the life years and
QALYs that would be accrued for individuals with each
diagnosis.
The results of the two submodels were combined to
give a full incremental analysis of costs and QALYs [9].
The management submodel included a number of pos-
sible events: colonoscopy, colonoscopy complication, col-
onoscopy mortality, CRC incidence, metachronous CRC
incidence, CRC mortality, prophylactic hysterectomy,
prophylactic hysterectomy mortality, endometrial cancer
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tality. These events determined the costs incurred and life
years and QALYs accrued.
In line with the NICE reference case [10], the perspec-
tive of NHS and Personal Social Services was adopted
and costs and benefits were discounted by 3.5% per
annum. Costs were converted to pounds sterling (£)
using purchasing power parities [11] (where appropriate)
and adjusted to 2013/14 prices using the Hospital and
Community Health Services (HCHS) index [12]. Individ-
uals were simulated up to age 100 or until death.
Parameters relating to the natural histories of diseases,
the effectiveness of interventions and the impact on
HRQoL of diseases and interventions were sourced,
where possible, from national statistics and published lit-
erature. Where such values were not available, estimates
were sought from clinical experts, with priority given to
clinical data.
If data permitted, diagnostic test accuracy parameters
were estimated according to previous tests, e.g., separate
estimates of the test accuracy of BRAF V600E mutation
testing were used depending on whether IHC or MSI
was the preceding test. In some cases such estimates
were not available and it was necessary to assume the in-
dependence of diagnostic tests.
Colonoscopy was estimated to reduce the incidence of
index CRC (i.e., the first incident CRC in an individual)
using a hazard ratio of 0.387 estimated from a Finnish
cohort study [5]. Surveillance colonoscopy was estimated
to reduce the incidence of metachronous CRC (i.e., a
subsequent incident CRC) using a hazard ratio of 0.533
estimated from an Italian cohort study [13]. Individuals
were assumed to develop a maximum of two CRCs over
a lifetime. Colonoscopies were received every three years
in the Finnish cohort study [5] but occur every two years
in our decision model. The effectiveness of biennial col-
onoscopy may therefore be underestimated and we ad-
justed the cost of colonoscopies down by a third to
remove this bias (but keep true representations of the
number of colonoscopies and the associated risks). Col-
onoscopies were received every two years in the Italian
cohort study [13] but the same cost (reduced by a third)
was used for colonoscopies intended to prevent meta-
chronous CRC, which would bias cost-effectiveness in
favour of interventions. Sensitivity analyses investigated
the effect of colonoscopies being more costly and of sur-
veillance being less effective.
General population norms for HRQoL were included
based on Ara and Brazier [14]. No disutility was as-
sumed for individuals with CRC unless they had meta-
static cancer [15] (Dukes’ stage D), in which case a
disutility of 0.13 was applied [16]. Colonoscopy was as-
sumed not to affect HRQoL. Different types of colorectal
surgery were modelled but no HRQoL difference wasincluded in the base case [17]. No disutility was assumed
for endometrial cancer as most patients would be diag-
nosed with early stage cancer [8] and a study of 264
women found HRQoL was similar for early stage endo-
metrial cancer patients as for those in the general popu-
lation [18]. No disutility was assumed for prophylactic
H-BSO as it is not offered until childbearing would be
expected to be completed. Disutilities were applied to
account for the psychological impact of genetic testing
on HRQoL for four months [19].
Additional file 1 gives further details about our model-
ling approach for interested readers and to allow comple-
tion of the CHEERS checklist [20] in Additional file 2.
Additional file 3: Tables S1 and S2 detail and give
sources for the model parameters of the diagnostic and
management components respectively.
Results
Base case results
All strategies except Strategies 1(2) (family history only)
and 8 (direct mutation testing) had specificity over
99.5% in relation to probands. All strategies except Strat-
egy 1(2) had sensitivity of 60% or greater. Strategy 3 had
the highest positive predictive value (98.7%) and Strategy
7 had the highest negative predictive value (97.8%). The
use of BRAF V600E testing in strategies improved speci-
ficity without compromising sensitivity.
Table 2 gives the cost–utility results in the base case
and these are shown on the cost–utility plane in Figure 1.
Secondary outcomes across strategies are given in
Table 3.
Total discounted costs (across the population for an
annual cohort) ranged from £36.22 m for Strategy 1(1)
to £38.20 m for Strategy 8. The use of BRAF V600E test-
ing reduced total discounted costs as savings were made
in the number of diagnostic genetic tests.
Total discounted QALYs (across the population for an
annual cohort) ranged from 151,793 for Strategy 1(1) to
152,000 for Strategy 8. The use of BRAF V600E testing
slightly improved total discounted QALYs (<0.1 QALYs
across population).
Strategies 2, 4 and 6 were dominated by (i.e., were
more costly and less effective than) another strategy.
Strategies 1(2) and 3 were extended dominated, i.e., were
more costly and less effective than some combination of
other strategies. Strategies 1(1), 5, 7 and 8 were therefore
on the cost-effectiveness frontier (neither dominated nor
extended dominated), as shown in Figure 1. The ICER of
Strategy 8 versus Strategy 7 was £82,962/QALY, substan-
tially greater than the UK cost-effectiveness threshold of
£20,000 per QALY, suggesting that direct reflex muta-
tion testing is not cost-effective in early-onset CRC pa-
tients. At a willingness-to-pay of £20,000 per QALY,
Strategy 5 resulted in the greatest net health benefit (in
Table 2 Base case results representing an annual cohort from England (primary outcomes)
Strategy 1(2) 2 3 4 5 6 7 8
Incremental costs vs Strategy 1(1) [£ Thousands]
Diagnosis 48.9 662.7 578.5 599.6 586.0 636.9 1061.6 1336.6
CRC prevention 396.7 735.9 726.9 822.1 817.1 817.1 928.8 1065.7
CRC treatment −249.3 −646.9 −646.2 −725.5 −725.2 −725.2 −814.0 −848.8
EC prevention 210.4 338.1 333.2 377.3 374.5 374.5 427.0 499.6
EC treatment −21.7 −60.6 −60.6 −68.0 −68.0 −68.0 −76.2 −78.7
Total 384.9 1029.2 931.8 1005.4 984.5 1035.3 1527.1 1974.5
Incremental QALYs vs Strategy 1(1)
Short-term 0 −4.3 −4.1 −4.8 −4.6 −4.6 −5.5 −8.5
Long-term 63.9 164.0 163.9 184.0 183.9 183.9 206.4 214.8
Total 63.9 159.7 159.8 179.2 179.3 179.3 200.9 206.3
Cost–utility
ICER vs Strategy 1(1) [cost per QALY gained] £6021 £6444 £5831 £5610 £5491 £5774 £7601 £9571
ICER [cost per QALY gained] ED D ED D £5491 D £25106 £82962
INHB at WTP £20000/QALY vs 1(1) [QALYs] 44.7 108.3 113.2 129.0 130.1 127.5 124.5 107.6
Key: D, dominated; EC, endometrial cancer; ED, extended dominated; WTP, willingness-to-pay.
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against QALY gains) of 130.1 QALYs versus Strategy
1(1). Compared to Strategy 1(1), all strategies had an
ICER under £10,000/QALY and are therefore considered
cost-effective versus no testing.
Scenario analyses
We conducted scenario analyses investigating the impact
of altering the inclusion age range for reflex testing for
LS and of replacing BRAF testing with MLH1 methyla-
tion testing. We also conducted univariate sensitivity
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Figure 1 Cost–utility plane (base case results, representing an
annual cohort from England).Expanding the inclusion age range
We explored the impact of increasing the inclusion age
from 50 years to 60 years and to 70 years. A number of
parameters were altered for consistency, most notable of
these being: the number of probands offered reflex test-
ing was increased from 1,699 in the base case to 5,018
and 13,900 as CRC patients aged under 60 and 70 years
respectively are included; the prevalence of LS in the
probands was reduced from 8.4% in the base case to
5.7% and 3.8%.
In both scenarios Strategy 5 remained the most cost-
effective strategy at a willingness-to-pay of £20,000 per
QALY (Table 4). In both scenarios there was little differ-
ence in QALY gain between Strategy 7 and Strategy 8
but there were significant cost increases associated with
Strategy 8 which suggest universal reflex mutation test-
ing would definitely not be cost-effective in older CRC
patients. Strategy 5 remained cost-effective even when
the cost of colonoscopies was doubled which suggests
these results are fairly robust.
The INHB obtained when an age limit of 70 years was
used exceeded the INHBs for age limits of 50 and
60 years due to the increased population size. On aver-
age less benefit would be accrued for each individual
(and more CRC patients without LS would be subjected
to some amount of testing), but in aggregate results sug-
gest an age limit of 70 years is cost-effective.
Replacing BRAF mutation testing with MLH1
hypermethylation testing
MLH1 promotor hypermethylation causes microsatellite
instability and can masquerade as LS [21]. The detection
Table 3 Base case results representing an annual cohort from England (secondary outcomes)
Strategy 1(2) 2 3 4 5 6 7 8
Number of colonoscopies vs Strategy 1(1) (=4162) +1618 +3044 +3008 +3401 +3381 +3381 +3842 +4400
Life expectancy of index patient vs Strategy 1(1) (=13.82 years) +0.06 +0.10 +0.10 +0.12 +0.12 +0.12 +0.13 +0.14
Life expectancy of index patient with LS vs Strategy 1(1) (=12.93 years) +0.72 +1.24 +1.24 +1.39 +1.39 +1.39 +1.56 +1.61
Life expectancy of relative vs Strategy 1(1) (=37.38 years) +0.01 +0.05 +0.05 +0.05 +0.05 +0.05 +0.06 +0.06
Life expectancy of relative with LS vs Strategy 1(1) (=33.97 years) +0.31 +1.24 +1.24 +1.39 +1.39 +1.39 +1.56 +1.61
Expected number of CRCs vs Strategy 1(1) (=664.9) −8.36 −24.59 −24.56 −27.59 −27.57 −27.57 −30.95 −32.30
Expected number of ECs vs Strategy 1(1) (=53.8) −4.99 −14.29 −14.29 −16.03 −16.03 −16.03 −17.97 −18.55
Abbreviations: EC endometrial cancer.
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rule out LS unless other risk factors are present (e.g.,
early-onset CRC, family history).
We conducted a scenario analysis in which BRAF test-
ing in strategies was replaced by methylation testing. We
found that in this scenario ICERs versus Strategy 1(1)
did not change significantly from in the base case, but
there were small changes to costs and QALYs which
changed the strategies on the cost-effectiveness frontier.
In this scenario Strategy 4 now gives more QALYs than
Strategy 5 (and remains more expensive) and is therefore
no longer dominated. Strategy 4 in fact now gives the
greatest INHB at a willingness-to-pay of £20,000 per
QALY (129.0 QALYs), although this is still lower than
the INHB of Strategy 5 in the base case, which suggests
that methylation testing may not be as cost-effective as
BRAF testing, although the difference (if there is one) is
likely to be small.Table 4 Cost–utility when age limit is raised to 60 and
70 years (representing an annual cohort from England)
Scenario Base case (CRC
under 50 years)
CRC under
60 years
CRC under
70 years
Incremental costs of Strategy 5 vs Strategy 1(1) [£ Thousands]
Diagnosis 586.0 1590.5 4132.2
CRC prevention 817.1 1630.3 2990.5
CRC treatment −725.2 −1450.7 −2604.6
EC prevention 374.5 772.5 1430.4
EC treatment −68.0 −139.2 −247.9
Total 984.5 2403.4 5700.5
Incremental QALYs Strategy 5 vs Strategy 1(1)
Short-term −4.6 −9.5 −18.1
Long-term 183.9 322.4 574.4
Total 179.3 312.9 556.3
Cost–utility of Strategy 5 vs Strategy 1(1)
ICER [cost per QALY gained] £5491 £7681 £10247
INHB at WTP £20,000/QALY
[QALYs]
130.1 192.8 271.3
Abbreviations: EC endometrial cancer, WTP willingness-to-pay.Univariate sensitivity analyses
We conducted univariate sensitivity analyses on the ma-
jority of parameters (results are presented as tornado di-
agrams in Additional file 1). Strategy 5 remained cost-
effective versus Strategy 1(1) in all sensitivity analyses
except when prophylactic H-BSO was assumed to re-
duce utility by 0.1, in which case Strategy 1(1) (no test-
ing) dominated all strategies, i.e., it was the least costly
and gave the most QALYs. Strategy 8 (direct mutation
testing) was found to be cost-effective when the costs of
mutation tests for probands were halved – this gives an
indication that as costs of mutation testing decrease (in-
cluding through next generation sequencing), tumour-
based tests IHC, MSI and BRAF V600E may no longer
be necessary for cost-effective diagnosis. Notably, an-
other sensitivity analysis suggested that reflex testing re-
mains cost-effective even when no relatives are
identified for testing, with an ICER of £6,725/QALY
(higher than the £5,491/QALY base case with five rela-
tives identified but still below the £20,000/QALY cost-
effectiveness threshold). The relative robustness of our
results to this parameter is due to the inclusion of sig-
nificant risk-reducing measures for metachronous cancer
(colorectal and endometrial) in the proband and because
we find that testing in relatives leads to increased costs
as well as improved outcomes.
Impact on colonoscopy services
If Strategy 5 were introduced in England, we project that
the number of surveillance colonoscopies would increase
until a steady state of approximately 3,250 surveillance col-
onoscopies would be conducted per year, with an initial
growth rate of approximately 120 surveillance colonos-
copies per year (Figure 2). The steady state corresponds to
approximately two surveillance colonoscopies for each pro-
band tested per year with an initial growth rate of approxi-
mately one surveillance colonoscopy for each 14 probands
tested. These projections are based on the assumptions of
no demographic or epidemiological changes.
For example, a district general hospital serving a popu-
lation of 400,000 would expect to reach a steady state of
approximately 25 surveillance colonoscopies per year,
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Figure 2 Projected number of surveillance colonoscopies if Strategy
5 were to be introduced in England.
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oscopy per year. This would probably be a small impact
on colonoscopy services compared to interventions such
as the NHS Bowel Cancer Screening Programme, for
which approximately 1,000 colonoscopies are conducted
each week in the UK [22], corresponding to approxi-
mately 300 colonoscopies per year for the hypothetical
district general hospital.
A number needed to treat calculation suggests that ap-
proximately 90 additional colonoscopies would be needed
to prevent one CRC if Strategy 5 were to be introduced.
Colonoscopies also identify CRCs in early stages, thereby
improving survival. The combination of these and other
factors suggest 4–5 colonoscopies would be needed to
save one life year, and 6 colonoscopies would be needed to
save one QALY.
Discussion
Relation to previous findings
There are no comparable studies in the NHS but others
have evaluated the cost-effectiveness of strategies to
identify LS elsewhere. These have generally adopted a
similar approach to ours – the identification of LS in
early-onset CRC patients and in their relatives. Our re-
sults are broadly consistent with those of others that
age-targeted testing for LS with preliminary tests before
diagnostic mutation testing is cost-effective versus no
testing [23-28]. There is some disagreement whether dir-
ect diagnostic mutation testing would be cost-effective
versus no testing, but all studies agree that it would not
be cost-effective versus strategies with preliminary tests.
Our results also suggested that reflex testing would becost-effective even if relatives cannot be identified for
testing, while some previous analyses have identified this
as a very sensitive parameter for cost-effectiveness
[25-28]. Some of these failed to include any potential
direct benefits to probands in terms of prevention of
metachronous cancer [25,26]. Dinh, Rosner et al. consid-
ered the approach of general population screening using
a risk prediction tool (PREMM126) [29] in primary care
with a comparator arm of “current practice” and found
that screening individuals at various ages with a pre-
dicted risk of carrying LS of 5% or greater was cost-
effective [30]. It is not clear whether such a strategy
would be cost-effective versus systematic reflex testing as
proposed in this analysis, since current practice was as-
sumed to include low awareness of Lynch syndrome and
limited availability of IHC and MSI. While the approach
of Dinh, Rosner et al. could result in faster identification
of families with Lynch syndrome than reflex testing of
CRC patients, it would also entail a significant and pos-
sibly disruptive burden on primary care when initiated,
which also may not have been costed in their analysis.
Strengths and limitations
We did not include costs of surveillance for gynaeco-
logical cancer, although this has been recommended in
clinical guidance [31], because we did not find evidence
of the effectiveness of such surveillance, and clinical
opinion we have sought suggests it is not effective at
identifying ovarian cancer and not always used in prac-
tice. Given that this surveillance can be costly (estimated
at over $350 per year [32]), it would seem prudent to
evaluate the effectiveness and cost-effectiveness of gy-
naecological surveillance before recommending it to
women with LS, particularly as it may displace prophy-
lactic surgery which has been shown to be effective in
preventing gynaecological cancers [8].
We have not modelled ovarian cancer or other cancers
associated with LS. Ovarian cancer affects fewer individ-
uals with LS than CRC or endometrial cancer [33] but is
associated with poor survival [34], so it is likely that fail-
ure to model ovarian cancer underestimates the benefits
of prophylactic bilateral salpingo-oophorectomy (which is
already modelled as a cost for endometrial cancer preven-
tion) and in this respect our analysis underestimates the
cost-effectiveness of testing for LS. The risks of other can-
cers associated with LS are highly uncertain and it is not
clear whether risk-reducing measures such as surveillance
are effective or could be cost-effective for these cancers.
We have not included chemoprevention in our ana-
lysis, although recent developments suggest that chemo-
prevention may have a role in the management of
individuals with LS [31], with the CAPP2 study strongly
suggesting a reduction in the risk of associated cancers
in individuals with LS due to long-term aspirin [35] and
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of LNG-IUS in preventing endometrial cancer in indi-
viduals with LS [36]. These are low cost interventions
which would very likely be cost-effective if clinical bene-
fit is confirmed and quantified.
When considering the generalizability of our analysis
it is important to consider infrastructure requirements
to ensure that testing is completed and the results used
appropriately. While much of this infrastructure
already exists in the UK (particularly for testing) there
may be local variation in follow-up and surveillance
after diagnosis.
Areas of uncertainty
Uncertainty exists regarding the impact of prophylactic
H-BSO on HRQoL; in a sensitivity analysis this was
found to have a drastic effect on cost–utility (since it is
offered to so many individuals in the population), result-
ing in Strategy 1(1) (no testing) being less costly and
more effective than all others. If it is thought that a dis-
utility of 0.1 is plausible, studies should be conducted to
estimate the true impact on HRQoL as a priority. We
note that the best source for utility values following hys-
terectomy identified in a recent economic study [37]
involving hysterectomy (in this case for menorrhagia)
was a Finnish study using EQ-5D to compare the
levonorgestrel-releasing intrauterine system (LNG-
IUS) with hysterectomy over five years [38]. Partici-
pants randomised to hysterectomy in this study had an
average “EQ-5D index” of 0.88 five years after random-
isation. While the EQ-5D index is not a preference-
based utility value (it is instead a regression model
mapping EQ-5D states to EQ-5D VAS measurements),
it is scaled 0–1 and the Finnish female population ap-
pears to measure at 0.91 for ages 35–44 and 0.89 for ages
45–54 [39], which suggests that the long-term disutility of
hysterectomy is likely to be small. It may be possible that
the addition of bilateral salpingo-oophorectomy results in
reduced HRQoL which is not measured by Hurskainen
et al. since only 7/109 participants received bilateral
salpingo-oophorectomy and results for these participants
are not presented separately [38].
Other considerations
Next generation sequencing may lead to significant cost
reductions in mutation testing for LS, meaning that in the
future direct mutation testing may be cost-effective. In the
past there have been concerns that direct mutation testing
could lead to significant psychological harms but recent
improvements in the classification of variants of uncertain
significance in LS [2] and the encouraging interim results
from the Mainstreaming Cancer Genetics programme [40]
could result in a shift towards direct mutation testing for
hereditary cancer syndromes such as LS.A very recent development in tumour testing for LS is
the use of IHC to detect BRAF V600E mutations, the
performance of which has been demonstrated to varying
degrees [41,42]. If sufficient diagnostic performance can
be obtained from this test it may be possible to perform
sensitive and specific tumour-based testing for LS
purely using IHC and avoiding the cost of molecular
genetic tests.
Microsatellite instability has been shown to be predict-
ive of the efficacy of fluorouracil-based adjuvant chemo-
therapy [43], which has led to suggestions that MMR
proficiency should be evaluated in all CRC patients who
might receive adjuvant chemotherapy (Stage II and
above). If testing for MMR proficiency becomes wide-
spread then the incremental cost of testing for LS will
decrease (since some tumour-based testing will already
have been conducted for many patients).Conclusions
The results presented suggest that reflex testing for LS
would be a cost-effective use of limited NHS resources
and in the base case of testing in newly-diagnosed CRC
patients aged under 50 years would not create an
excessive additional burden for colonoscopy services. As
cost-effectiveness may be a perceived barrier to the
introduction of reflex testing, these results may result in
national policy change.
Maximum net health benefit was estimated to be ob-
tained when all newly-diagnosed CRC patients aged
under 70 years are tested. Reflex testing remained
cost-effective even when the cost of colonoscopies
(one of the most sensitive parameters) was doubled,
which suggests there is some robustness in this con-
clusion. Decision makers will likely want to consider
all sources of uncertainty and also consider budget im-
pact and the impact on colonoscopy services of any
policy changes.
We recommend further research to establish whether
it is cost-effective to perform reflex testing in other LS-
associated cancers (such as endometrial and ovarian
cancer). We also recommend a controlled study of
HRQoL in women following prophylactic H-BSO using
the EQ-5D tool to ensure that this does not lead to an
overall loss of QALYs. We further recommend that
the effectiveness of gynaecological surveillance for
endometrial and ovarian cancer in women with LS is
evaluated.Research ethics
No human subjects, human material, or human data
were involved in this research, which is based on litera-
ture review and software modelling.
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